globenewswire

AI GPU Rental is offering short-term ways to invest in AI computing power. New users can also get up to $128 in free credits to try it.

RIYADH, Saudi Arabia, June 13, 2026 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH) will use its participation at HLTH Europe 2026, taking place from June 15 to 18 in Amsterdam, to advance a clear message: artificial intelligence in healthcare will only scale when institutions can prove that it is safe, reliable, governed, and trusted by clinicians and patients.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In BitGo To Contact Him Directly To Discuss Their Options

FemiCore bladder control capsules 2026 — ingredient information, probiotic strain details, official website verification guidance, and the counterfeit-marketplace red flags consumers are encouraged to be aware of in the women's health supplement category.

Join XRP and top assets through AI-driven automated strategies with daily settlement—no manual trading needed.

شنغهاي، الصين, June 13, 2026 (GLOBE NEWSWIRE) -- في خطوة تشكل محطة بارزة لقطاع السيارات الكهربائية الفاخرة عالمياً، سجلت سيارة «فريلاندر 8» (FREELANDER 8) ظهورها العلني الأول خلال فعاليات "منتدى أبوظبي للاستثمار - جلسة شنغهاي الخاصة" الذي عُقد في فندق "ذا بنينسولا شنغهاي" في 11 يونيو 2026. ويأتي هذا العرض الأولي في الوقت الذي تستعد فيه العلامة التجارية الفاخرة لإطلاق هويتها رسمياً في منطقة الشرق الأوسط من العاصمة الإماراتية أبوظبي.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.¹ The results showed that TALVEY^® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).¹ Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.¹